P opulation studies have reported that Hispanic Americans with heart failure (HF) are more likely to be younger and to have higher prevalence of diabetes, dyslipidemia, kidney disease, and reduced left ventricular ejection fraction (LVEF) compared with non-Hispanic whites. [1] [2] [3] [4] [5] Furthermore, Hispanics have been shown to have more frequent hospitalization and readmission but better short-term survival than non-Hispanic whites. 1, 6 Most of these data, however, have been drawn from selective populations and may not accurately represent the clinical characteristics and outcomes of Hispanics with HF.
Clinical Perspective on p 175
Although Hispanics constitute the leading ethnic group in the United States in number and growth rate, 7 data on potential differences between Hispanic patients with preserved EF (PEF) and those with reduced EF (REF) are sparse. Examining unique features between these groups are relevant, considering the limited evidence on the predominant etiology of HF in Hispanics and on treatments specific for HF patients with PEF. Using data from the American Heart Association's Get With The Guidelines (GWTG)-HF registry, the present study aims to compare characteristics, quality of care, and outcomes between nationwide populations of Hispanic and non-Hispanic whites hospitalized for HF with either PEF or REF. Additionally, we evaluate temporal trends in adherence to process-of-care measures for both groups.
Methods

Data Collection
Data were collected from the GWTG-HF registry, an ongoing national, voluntary program initiated in 2005 to improve adherence to quality of care guidelines for patients hospitalized with HF. The design and data variables gathered in the GWTG program have been previously published. 8 -10 Eligible patients admitted to participating hospitals were consecutively enrolled irrespective of their EF. Data elements, including patient characteristics, medical history, medications, laboratory data, contraindications to treatment, inpatient care, outcomes, and hospital characteristics were entered into an online interactive case report form and patient management tool (Outcome Sciences, Inc, Cambridge, MA). Using standardized definitions, trained personnel abstracted the data. All participating institutions were required to comply with local regulatory and privacy guidelines and, if required, to secure institutional review board approval. Because data were used primarily at the local site for quality improvement, sites were granted a waiver of informed consent under the common rule. Through an Internet-based system, data quality was monitored for completeness and accuracy. Outcome Sciences, Inc, served as the data collection and coordinating center for GWTG. The Duke Clinical Research Institute served as the data analysis center and examined the aggregate deidentified data for research purposes.
Similar to methods used in national cardiovascular registries, race/ethnicity data were recorded by patient self-reporting or by highly trained admissions or medical staff during registration. Race was recorded as part of a multiple-choice data entry tool (ie, white, black, Asian, American Indian/Alaska native, and Native Hawaiian/ Pacific Islander). A separate data element for Hispanic ethnicity (ie, yes versus no/not documented) was also implemented. For this study, patients were designated into Hispanic or non-Hispanic white categories, based on the racial and ethnic data collected. PEF was defined as EF quantified to be Ͼ40% or qualitatively described as normal or mildly impaired. Patients were considered to have REF if they had an EF Ͻ40% or if they were documented to have moderate to severe LV dysfunction.
Study Population
To be eligible for the GWTG-HF, patients had to be hospitalized with an episode of new or worsening HF as the primary reason for admission or with significant HF symptoms that developed during hospitalization in which HF was the primary discharge diagnosis. The study population consisted of hospitals fully participating in GWTG-HF who entered demographic, clinical, and quality data using the GWTG Patient Management Tool. Hospitals participating in GWTG-HF in only a very limited fashion in which demographic and clinical data were not collected were not included in this study. There were a total of 115 015 patients admitted with HF to 264 participating sites. After excluding racial/ethnic groups other than Hispanic or non-Hispanic white (nϭ30 935), patients with no documented EF (nϭ5419), and those from sites in Puerto Rico (nϭ685), the final study population was composed of 77 976 patients admitted from January 1, 2005, through March 29, 2010, to 247 hospitals from different geographic regions of the United States.
Outcome Measures
Based on HF practice guidelines proposed by the American Heart Association (AHA) and the American College of Cardiology, performance measures assessed by GWTG-HF at discharge for patients with REF included use of an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker, ␤-blockers, 1 of the 3 specific guideline-recommended ␤-blockers for HF, and aldosterone antagonists; provision of HF-specific discharge instructions; smok-ing cessation counseling for eligible patients; anticoagulation for atrial fibrillation, and; blood pressure control. 11 Because no evidence-based HF medical therapies were available for PEF, quality indicators evaluated for patients with PEF were limited to discharge instructions, smoking cessation counseling, anticoagulation for atrial fibrillation, and blood pressure control. Two summary measures were used to characterize the overall processes of care. The proportion of patients who received all interventions for which they were eligible defined the binary "all-or-none" process performance measure. The total number of performance measure interventions provided among eligible patients divided by the total number of possible interventions defined the "opportunity-based" overall composite performance measure. In-hospital clinical outcomes included mortality and length of stay (excluding transfer-ins and transfer-outs). We also examined discharge destination (home or skilled nursing facility) and discharge symptoms (better/asymptomatic or better/symptomatic).
Statistical Analysis
Descriptive baseline data on Hispanic and non-Hispanic white patients categorized according to PEF and REF group were presented as percentages and compared using 2 tests for categorical variables. Medians and 25th and 75th percentiles were reported for and Wilcoxon rank-sum tests were used to compare continuous and ordinal categorical variables.
Performance measures were analyzed among eligible patients without contraindications, intolerance, or other reasons documented by the provider. The relationship between race/ethnicity and compliance with individual performance measure, the summary measures, and in-hospital outcomes were then examined using multivariable generalized estimating equation (GEE) logistic regression models, which accounted for the correlation of data within hospitals. Variables in the model included Hispanic ethnicity, age, sex, body mass index (BMI), insurance status, history of atrial fibrillation or flutter, chronic obstructive pulmonary disease or asthma, diabetes, hyperlipidemia, hypertension, peripheral vascular disease, myocardial infarction, stroke or transient ischemic attack, HF, anemia, renal insufficiency, smoking, ischemic etiology of HF, heart rate at admission, systolic blood pressure at admission, hospital size, hospital type, region, and percentage of Hispanics treated. GEEs were used to account for within-hospital clustering because patients at the same hospital are more likely to be treated similarly relative to patients in other hospitals. In view of significant age differences between the 2 ethnic groups, age-stratified analyses by age groups (ie, Ͻ45, Ͼ45 and Ͻ65, Ͼ65 and Ͻ85, Ͼ85 years) were performed for the 2 summary quality measures, mortality and length of stay. Age-ethnicity and geographic region-ethnicity interactions were also analyzed.
Missing data were minimal (Ͻ5%) for most variables used in the models, with few exceptions, including BMI (PEF: 22.8%, REF: 21 .6%), admission systolic blood pressure (PEF: 10.4%, REF: 9.7%), and heart rate (PEF: 12.2%, REF: 11.7%). In the primary analysis, patients with missing BMI were excluded and other missing variables imputed as follows: systolic blood pressure and heart rates to the median, sex to male, and insurance to Medicare if 65 years or older, other if younger. Missing hospital characteristics were excluded from adjusted models. In a secondary analysis, patients with missing BMI were not excluded and BMI was imputed to the median.
To evaluate how the summary measures changed over time for each racial/ethnic group within either EF category, we developed a GEE logistic regression model that adjusted for calendar time using the same patient and hospital characteristics noted above. Statistical significance for all tests was defined as PϽ0.01. All statistical analyses were performed with SAS software version 9.1 (SAS Institute, Cary, NC). The authors had full access to the data and take full responsibility for its integrity. All authors have read and agreed to the manuscript as written. Table 1 . Among patients with PEF, 38.3% of Hispanics were younger than 66 years. Hispanics with PEF were more likely to have a nonischemic etiology of HF and to have more elevated blood pressure and serum creatinine on admission, whereas non-Hispanic white patients with PEF had significantly higher NT-pro-brain natriuretic peptide (BNP) levels. In the REF group, nearly half of Hispanics were younger than 66 years. Although all patients with REF were more likely to have an ischemic etiology, the percentage was significantly lower in Hispanics than among non-Hispanic whites (57.1% versus 65.8%; PϽ0.0001). Non-Hispanic whites with REF were more likely to have higher levels of blood urea nitrogen, BNP, and NT-proBNP than Hispanics.
Results
Patient and Hospital Characteristics
Irrespective of EF, Hispanics were more likely to be younger and to have diabetes, hypertension, and dialysis dependence, whereas non-Hispanic whites were more likely to have coronary artery disease and atrial fibrillation. Hispanics also had higher BMI and a markedly larger proportion had no or undocumented insurance or Medicaid coverage than non-Hispanic whites. Moreover, Hispanics were more likely to be not on any cardiac medications before hospitalization (PEF: 1.6 versus 0.6%, REF: 3.0 versus 1.6%; PϽ0.0001). Compared with non-Hispanic whites, more Hispanics with either PEF or REF were admitted to hospitals that were larger, located in the West or Northeast, and admitted a higher percentage of Hispanics per site.
Quality of Care
Adherence to quality measures and the composite measures of all-or-none and opportunity-based care by EF group and race/ethnicity are shown in Table 2 . In the PEF group, Hispanics were more likely to receive discharge instructions (89.8% versus 86.8%; PϽ0.0001) but were less likely to have controlled blood pressure at discharge (65.0% versus 72.0%; PϽ0.0001) than non-Hispanic whites. Provision of smoking cessation counseling and warfarin for atrial fibrillation was similar.
Among those with REF, adherence to 4 of 8 performance measures (ACE-I or angiotensin receptor blocker use, ␤-blocker use, evidence-based ␤-blocker use, and receipt of discharge instructions) was higher in Hispanics than in non-Hispanic whites. All-or-none and opportunity-based measures of care were higher in Hispanics than in non-Hispanic whites with REF but were comparable in patients with PEF.
In-Hospital Outcomes and Discharge Status
Unadjusted in-hospital mortality rates varied between racial/ ethnic groups according to EF (Table 3 ). Although Hispanics with PEF were less likely to die than non-Hispanic whites during HF hospitalization (1.4% versus 2.9%; PϽ0.0001), there was no significant difference in unadjusted in-hospital death between Hispanics (2.6%) and non-Hispanic whites (3.3%) with REF (Pϭ0.0231).
In both PEF and REF groups, a higher percentage of Hispanics were discharged home, whereas fewer were discharged to a skilled nursing facility compared with non-Hispanic whites. Median length of stay (4.0 days) was similar between racial/ethnic populations, irrespective of EF group. At discharge for both EF groups, Hispanics were more likely to report feeling better/asymptomatic, whereas non-Hispanic whites were more likely to report being better but with symptoms.
Multivariate Analysis
After multivariable GEE adjustment for patient-and hospitalrelated variables, differences in application of performance and composite measures diminished between Hispanic and non-Hispanic white patients ( Supplement  Tables II and III) . Of note, Hispanics with PEF ages 65 to 85 years were less likely to receive all-or-none (OR, 0.74; 95% CI, 0.63-0.86; PϽ0.001) and opportunity-based composite care (OR, 0.79; 95% CI, 0.67-0.93; Pϭ0.005) than agematched non-Hispanic whites. The odds of exceeding the Supplement Tables IV and V) . Using an alternative approach of simple imputation of missing values to the median did not alter the qualitative results of the main analysis.
Temporal Trends in Care
Overall, the quality of HF care improved substantially through the study period for both racial/ethnic groups, regard- PEF indicates heart failure with preserved ejection fraction; REF, heart failure with reduced ejection fraction; PVD, peripheral vascular disease; CAD, coronary artery disease; MI, myocardial infarction; CVA, cerebrovascular accident; TIA, transient ischemic attack; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; BNP, brain natriuretic peptide. Supplement Table VIII ).
Table 2. Adherence to Performance Measures Including All-or-None and Opportunity-Based Care Between Hispanics and Non-Hispanic Whites by Ejection Fraction Group: Unadjusted Analyses
Discussion
Hispanics comprise a key study population in HF clinical care and research. In addition to their population size, Hispanics are challenged with high cardiometabolic risk and multiple barriers to health care that may adversely affect the outcomes of patients with HF. 12 Before this analysis, no large-scale study has distinguished the clinical profile, outcomes, and quality of care between Hispanics admitted for HF with either PEF or REF. Our results demonstrated some significant findings. First, there was a modestly higher percentage of Hispanics with reduced than preserved EF. Second, although the patient characteristics of Hispanics in either EF group were mainly similar, there was a predominance of nonischemic and ischemic etiology among those with PEF and REF, respectively. Third, Hispanics were more likely to survive than non-Hispanic whites during HF hospitalization, a finding Table 3 confined only in those with PEF. Finally, after adjustment for patient and hospital variables, quality of HF care for Hispanics and non-Hispanic whites was similar and improved analogously through the 5-year follow-up period, regardless of EF.
. Discharge Outcomes, Destination, and Symptoms Between Hispanics and Non-Hispanic Whites by Ejection Fraction Group: Unadjusted Analyses
We found that Hispanic patients hospitalized with HF were on average 8 -9 years younger and had higher rates of diabetes, hypertension, and overweight/obesity than their non-Hispanic white counterparts, confirming older registry data. [1] [2] [3] The Acute Decompensated Heart Failure Registry (ADHERE) showed that although they were much younger than non-Hispanic whites (67.2% versus 75%, PϽ0.0001), the prevalence of diabetes (58% versus 43%; PϽ0.0001), dyslipidemia (37% versus 36%, PϽ0.0001), and kidney disease (30% versus 29%, PϽ0.0001) was higher. 4 We observed a markedly lower prevalence of atrial fibrillation in Hispanics relative to non-Hispanic whites, similar to findings from another study. 13 Although the older age of non-Hispanic whites could account for their higher rates of atrial fibrillation, Hispanics had higher rates of hypertension and diabetes. Whether Hispanics are genetically less predisposed to have atrial fibrillation, despite their risk factors, needs further study. Notably, our data reflect previous observations that Hispanics have markedly poor medical insurance access. 14 Our finding that Hispanics were significantly less likely than non-Hispanic whites to be on any cardiac medications before HF admission is further evidence that access to medical care is an important source of health disparities for this population.
In this study, the principal cause of HF varied according to EF: Hispanics with PEF were more likely to have nonischemic cardiomyopathy (49.3%), whereas those with REF were more likely to have an ischemic cause (57.1%). These results suggest that their excessive cardiometabolic risk burden may be the predominant etiology of HF among Hispanics with PEF. Previous investigations have documented that insulin resistance is associated with changes in LV structure and diastolic function. [15] [16] [17] Furthermore, data have shown a greater influence of diabetes on structural LV abnormalities among Hispanics. 18 Importantly, we found a higher proportion of Hispanic HF patients with REF (54.2%) than PEF (45.8%), consistent with earlier reports. 2, 3, 5 Although there was a higher propensity for ischemia as cause of HF in Hispanics with REF, some reports have also indicated that longer duration of insulin resistance is independently associated with poorer LV systolic function. 19, 20 In-hospital mortality rates in Hispanic (1.4%) and non-Hispanic white patients (2.9%) with PEF were slightly lower than in Hispanics (2.6%) and non-Hispanic whites (3.3%) with REF, in agreement with data from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) (2.9% versus 3.9%; PϽ0.0001) and ADHERE (2.8% versus 3.9%; Pϭ0.005) studies. 21, 22 Similarly, a recent meta-analysis reported that mortality in patients with PEF was approximately half that seen among those with REF. 23 In contrast, a large Framingham study showed comparable survival between HF patients with PEF or REF, highlighting improvements in relative mortality reduction among patients with REF. 24 A novel finding of our study is that Hispanic patients with PEF, but not those with REF, had lower adjusted odds of in-hospital death than non-Hispanic whites. Although select databases have documented lower adjusted in-hospital (4.5% versus 5.1%, PϽ0.05) and 1-year mortality rates (25.4% versus 35.2%, PϽ0.001) in Hispanic HF patients than in non-Hispanic whites, these findings were not analyzed according to EF. 1, 6 In age-stratified analysis, Hispanics with PEF between 65-85 years old continued to have a higher likelihood of surviving during HF hospitalization than agematched non-Hispanic whites. This finding is noteworthy, particularly when considering that this age group represents the majority (Hispanics, 51.0%, and non-Hispanic whites, 56.6%) in either racial/ethnic population. A plausible explanation for this survival advantage is that Hispanics with PEF represent a group that is diagnosed early in their disease course. It is also likely that their hospitalization may be a marker of their first encounter with the health care system due to poor access to outpatient care and/or medications rather than an indicator of advanced disease. The lower NT-proBNP levels seen in Hispanics appear to support our hypothesis of milder disease severity. At the onset of REF or more advanced disease, however, this survival difference diminishes and the odds of in-hospital mortality tend to equalize between Hispanics and non-Hispanic white patients.
Racial/ethnic disparities in quality of care pertinent to Hispanic HF patients have been described. Earlier studies from Medicare and OPTIMIZE-HF populations demonstrated that Hispanics were less likely to have LV function assessment, be discharged on ACE-I, and receive discharge instructions. 25, 26 In contrast, a GWTG-HF report from 2005-2008 indicated comparable guideline-based care between Hispanics and non-Hispanic whites. 27 In this current GWTG-HF analysis spanning a 5-year period, we found no significant racial/ethnic disparities in adherence to performance measures among patients in either EF group, except for lower odds of receiving all-or-none care among Hispanics with PEF. Our finding that Hispanics with PEF ages 65-85 years were less likely to receive composite care than age-matched non-Hispanic whites identifies a target for improved care for the majority of this population. Our results also potentially demonstrate the value of a quality initiative program such as the GWTG-HF in increasing adherence to guideline-recommended interventions for HF through each year of participation, irrespective of ethnicity and EF. Such improvements are similar to findings among patients with acute myocardial infarction in the GWTG-coronary artery disease program. 28 We recognize some limitations of the study. Foremost, our results can be interpreted only in the context of patients hospitalized with HF. Postdischarge data, such as readmissions and medication compliance, are lacking. In view of data showing that patients who are discharged from hospitals with early follow-up have fewer readmissions, future investigation should examine whether HF readmissions among Hispanics may be "preventable" with better access to outpatient care. 29 Race/ ethnicity designation was recorded by administrative staff or admitting/nursing providers. Data subcategorized by Hispanic nationality, unavailable in the registry, may reveal differences in risk factors, acculturation and health care access. Variables including New York Heart Association functional class, socioeconomic status, educational level and health literacy were not collected. Thus, there was no correction in the models for patients' income, educational level, or health literacy that may be important as these may impact health care access, as well as disease severity at presentation, delays in seeking treatment, and/or discharge to home or skilled nursing facility. Because of the large study population, several differences that attained statistical significance may not necessarily represent clinical relevance. Residual unmeasured confounding variables may account for some or all of these findings. Voluntary institutional participation in the GWTG-HF program may represent hospitals that are more motivated in quality improvement and may therefore have slightly better outcomes than nonrepresented centers in the United States.
In conclusion, this contemporary analysis of the GWTG-HF database found that although there were no significant differences in the clinical characteristics of Hispanics stratified by EF, a nonischemic etiology was more common among patients with PEF, whereas an ischemic cause was more likely among those with REF. Despite having significant comorbidities, Hispanics with PEF but not those with REF had better in-hospital survival than non-Hispanic white patients, even after adjusting for differences in age. The survival difference was concentrated in the 65-85 age group. Quality of HF care was similar and improved progressively through the 5-year study period, underscoring the potential benefit of a process-of-care improvement program in advancing healthcare delivery, irrespective of race/ethnicity or EF.
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